Other languages DiaMedica Therapeutics Inc.

Equities

DMAC

CA25253X2077

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-01 pm EDT			5-day change	1st Jan Change
2.59 ^USD	+2.37%		+7.02%	-8.80%

Apr. 17	DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment	MT
Apr. 17	DiaMedica Therapeutics Inc. Announces First Patient Dosed in Relaunch of Its Pivotal Phase /3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

DiaMedica Therapeutics Inc. Announces First Patient Dosed in Relaunch of Its Pivotal Phase /3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke	Apr. 17
DiaMedica Therapeutics Inc. Announces Executive Changes	Apr. 10
DiaMedica Therapeutics Files $100 Million Mixed Shelf	Mar. 21
DiaMedica Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19
DiaMedica Therapeutics Names Lorianne Masuoka as Chief Medical Officer	Jan. 22
DiaMedica Therapeutics Inc. Appoints Dr. Lorianne Masuoka as Chief Medical Officer	Jan. 22
DiaMedica Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Top Premarket Gainers	23-10-25
DiaMedica Therapeutics Inc. Announces the Appointment of Ambarish Shah as Chief Technology Officer	23-09-12
Diamedica Therapeutics Inc. Announces Management Changes	23-09-05
DiaMedica Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Insider Buy: Diamedica Therapeutics	23-06-27
Insider Buy: Diamedica Therapeutics	23-06-26
Insider Buy: Diamedica Therapeutics	23-06-26
DiaMedica Therapeutics Announces US FDA's Removal of Clinical Hold on Phase 2/3 Trial for Ischemic Stroke Treatment DM199	23-06-21
DiaMedica Therapeutics Inc. Announces That the FDA Has Removed the Clinical Hold on Dm199 Phase 2/3 Trial Forschemic Stroke	23-06-21
Diamedica Therapeutics Announces Appointment of Richard Kuntz to the Board of Directors	23-05-30
Diamedica Therapeutics Inc. Files Complete Clinical Hold Response with the U.S. Food and Drug Administration Regarding the Status of the Remedy2 Study	23-05-22
DiaMedica Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
DiaMedica Therapeutics Appoints Tanya Lewis to its Board of Directors	23-04-16

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages DiaMedica Therapeutics Inc.

Equities

DMAC

CA25253X2077

Other languages

Filters